Trademark: 78867342
Word
SAGENT PHARMACEUTICALS
Status
Dead
Status Code
606
Status Date
Saturday, April 30, 2011
Serial Number
78867342
Mark Type
4000
Filing Date
Friday, April 21, 2006
Published for Opposition
Tuesday, February 5, 2008
Abandoned Date
Saturday, April 30, 2011

Trademark Owner History
SAGENT HOLDING CO. - 1st New Owner After Publication
New Hisun Inc - Owner At Publication

Classifications
5 Pharmaceuticals, namely, alkalizing agents, analgesics and anesthetics, antacids, anticholinergics, antihistamines, anti-inflammatory agents, anticonvulsants, antidotes, antiemetics, antipsychotics, anxiolytics, blood modifiers, bronchodialators, diuretics, hormones, diluents, electrolytes, vitamins, oncolytics, immunosuppressive agents, transplantation agents, imaging agents, and sensitizing agents for chemotherapy-resistant tumors; Pre-filled syringes sold filled with alkalizing agents; pre-filled syringes sold filled with analgesics; pre-filled syringes sold filled with anesthetics; pre-filled syringes sold filled with antacids; pre-filled syringes sold filled with anticholinergics; pre-filled syringes sold filled with antihistamines; pre-filled syringes sold filled with anti-infectives; pre-filled syringes sold filled with anti-inflammatory agents; pre-filled syringes sold filled with anticonvulsants; pre-filled syringes sold filled with antidotes; pre-filled syringes sold filled with antiemetics; pre-filled syringes sold filled with antipsychotics; pre-filled syringes sold filled with anxiolytics; pre-filled syringes sold filled with blood modifiers; pre-filled syringes sold filled with bronchodialators; pre-filled syringes sold filled with cardiovasculars; pre-filled syringes sold filled with diuretics; pre-filled syringes sold filled with hormones; pre-filled syringes sold filled with diluents; pre-filled syringes sold filled with electrolytes; pre-filled syringes sold filled with vitamins; pre-filled syringes sold filled with oncolytics; pre-filled syringes sold filled with immunosuppressive agents; pre-filled syringes sold filled with transplantation agents; pre-filled syringes sold filled with imaging agents; pre-filled syringes sold filled with vascular targeting agents; pre-filled syringes sold filled with sensitizing agents for chemotherapy-resistant tumors; Safety syringe devices sold filled with alkalizing agents; safety syringe devices sold filled with analgesics; safety syringe devices sold filled with anesthetics; safety syringe devices sold filled with antacids; safety syringe devices sold filled with anticholinergics; safety syringe devices sold filled with antihistamines; safety syringe devices sold filled with anti-infectives; safety syringe devices sold filled with anti-inflammatory agents; safety syringe devices sold filled with anticonvulsants; safety syringe devices sold filled with antidotes; safety syringe devices sold filled with antiemetics; safety syringe devices sold filled with antipsychotics; safety syringe devices sold filled with anxiolytics; safety syringe devices sold filled with blood modifiers; safety syringe devices sold filled with bronchodialators; safety syringe devices sold filled with cardiovasculars; safety syringe devices sold filled with diuretics; safety syringe devices sold filled with hormones; safety syringe devices sold filled with diluents; safety syringe devices sold filled with electrolytes; safety syringe devices sold filled with vitamins; safety syringe devices sold filled with oncolytics; safety syringe devices sold filled with immunosuppressive agents; safety syringe devices sold filled with transplantation agents; safety syringe devices sold filled with imaging agents; safety syringe devices sold filled with vascular targeting agents; safety syringe devices sold filled with sensitizing agents for chemotherapy-resistant tumors; Pharmaceuticals for treatment of cancer; pharmaceuticals to treat vascular diseases; Drug delivery systems sold as an integral component of drugs, namely, intradermal injection system for injection of anesthetics; Injectable drugs and therapeutic solutions for the treatment of cancer injectable drugs and therapeutic solutions for the treatment of psychotic disorders; injectable drugs and therapeutic solutions for the treatment of pain; injectable drugs and therapeutic solutions for the treatment of kidney disease; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies; injectable drugs and therapeutic solutions for the treatment of heartburn; injectable drugs and therapeutic solutions for the treatment of anxiety; injectable drugs and therapeutic solutions for immunosuppression; injectable drugs and therapeutic solutions for imaging; injectable drugs and therapeutic solutions for the treatment of seizures; Injectable drugs and therapeutic solutions for the treatment of cancer and vascular diseases sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of psychotic disorders sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of pain sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of allergies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of infections sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of cardiovascular disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of kidney disease sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of hormonal imbalances sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of vitamin deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of electrolyte deficiencies sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of heartburn sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of anxiety sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for immunosuppression sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for imaging sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors; injectable drugs and therapeutic solutions for the treatment of seizures sold in kits comprising pre-filled IV bags with devices for intravenous administration, namely, transfer pins, vials, needles, and adaptors
"PHARMACEUTICALS"

Trademark Events
Oct 9, 2012
Abandonment Notice Mailed - No Use Statement Filed
Oct 9, 2012
Abandonment - No Use Statement Filed
Oct 22, 2010
Notice Of Approval Of Extension Request E-Mailed
Oct 21, 2010
Extension 5 Granted
Oct 14, 2010
Extension 5 Filed
Oct 14, 2010
Teas Extension Received
Apr 27, 2010
Notice Of Approval Of Extension Request E-Mailed
Apr 26, 2010
Extension 4 Granted
Apr 15, 2010
Extension 4 Filed
Apr 15, 2010
Teas Extension Received
Nov 2, 2009
Extension 3 Granted
Oct 29, 2009
Extension 3 Filed
Oct 29, 2009
Teas Extension Received
Mar 27, 2009
Divisional Processing Complete
Mar 6, 2009
Divisional Request Received
Mar 27, 2009
Extension 2 Granted
Mar 6, 2009
Extension 2 Filed
Mar 27, 2009
Case Assigned To Intent To Use Paralegal
Mar 6, 2009
Teas Request To Divide Received
Mar 6, 2009
Teas Extension Received
Mar 6, 2009
Teas Statement Of Use Received
Mar 4, 2009
Automatic Update Of Assignment Of Ownership
Oct 29, 2008
Extension 1 Granted
Oct 29, 2008
Extension 1 Filed
Oct 29, 2008
Teas Extension Received
Apr 29, 2008
Noa Mailed - Sou Required From Applicant
Feb 5, 2008
Published For Opposition
Jan 16, 2008
Notice Of Publication
Dec 14, 2007
Withdrawn From Pub - Og Review Query
Dec 1, 2007
Law Office Publication Review Completed
Dec 1, 2007
Assigned To Lie
Oct 26, 2007
Approved For Pub - Principal Register
Oct 26, 2007
Examiner's Amendment Entered
Oct 26, 2007
Notification Of Examiners Amendment E-Mailed
Oct 26, 2007
Examiners Amendment E-Mailed
Oct 26, 2007
Examiners Amendment -Written
Sep 29, 2007
Teas/Email Correspondence Entered
Sep 28, 2007
Correspondence Received In Law Office
Sep 28, 2007
Teas Response To Office Action Received
Aug 14, 2007
Notification Of Non-Final Action E-Mailed
Aug 14, 2007
Non-Final Action E-Mailed
Aug 14, 2007
Non-Final Action Written
Jul 24, 2007
Teas/Email Correspondence Entered
Jul 24, 2007
Correspondence Received In Law Office
Jul 24, 2007
Teas Response To Office Action Received
Jun 12, 2007
Notification Of Non-Final Action E-Mailed
Jun 12, 2007
Non-Final Action E-Mailed
Jun 12, 2007
Non-Final Action Written
Jun 11, 2007
Petition Granted - Remail Office Action
Jun 7, 2007
Attorney Revoked And/Or Appointed
Jun 7, 2007
Teas Revoke/Appoint Attorney Received
May 7, 2007
Petition To Revive-Received
May 7, 2007
Paper Received
Apr 25, 2007
Abandonment Notice Mailed - Failure To Respond
Apr 25, 2007
Abandonment - Failure To Respond Or Late Response
Sep 27, 2006
Non-Final Action E-Mailed
Sep 27, 2006
Non-Final Action Written
Sep 25, 2006
Assigned To Examiner
Apr 27, 2006
New Application Entered In Tram

Trademark Alertz updated from USPTO on 2030-01-24